Platelet aggregation-IN-3

• Description:

  Platelet aggregation-IN-3 (Compound 5) is a ligand for H2 histamine receptors, α2 (A, C) -adrenergic receptors (α2-AR), and 5-HT2 (B, C) serotonin receptors. Platelet aggregation-IN-3 can inhibit platelet aggregation induced by ADP and collagen and can also modulate tumour cell-induced platelet aggregation (TCIPA) . Platelet aggregation-IN-3 is promising for research of antiplatelet therapy in cardiovascular diseases and the prevention of cancer-related thrombosis and tumour metastasis[1].

• UNSPSC:

  12352005

• Target:

  5-HT Receptor; Adrenergic Receptor; Histamine Receptor

• Related Pathways:

  GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer; Cardiovascular Disease

• Smiles:

  C1(NC2=CC=C3C(CCCC3)=C2)=NCCN1.Cl

• Molecular Formula:

  C13H18ClN3

• Molecular Weight:

  251.76

• References & Citations:

  [1]Hante NK, et al. Effect of mono-guanidine-like derivatives on platelet aggregation and tumour cell induced platelet aggregation. RSC Med Chem. 2025 Jan 31;16 (4) :1695-1704.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  5-HT2 Receptor; H2 Receptor; Histamine Receptor; α adrenergic receptor

• CAS Number:

  [1029802-21-8]